Close Menu

Ronald Matricaria has been appointed to the board of directors of Invitrogen, the company announced last week. He replaces William Mercer, who is retiring. Matricaria was formerly the chairman and CEO of St. Jude Medical, where he increased revenues from $225 million to more than $1 billion. Prior to that, he worked for Eli Lilly, serving as CEO of Lilly subsidiary Cardiac Pacemakers and as executive vice president of the pharmaceutical division of Eli Lilly, in addition to other roles.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.

Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.

Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.